Heartworm Preventative

Verify with FDA CVM →

69 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
69
Total Reports
5
Deaths Reported
720.0%
Death Rate

Active Ingredients

Heartworm Preventative

Administration Routes

OralUnknownSubcutaneousParenteral

Species Affected

Dog 69

Most Affected Breeds

Retriever - Labrador 11
Crossbred Canine/dog 10
Shepherd Dog - German 4
Retriever - Golden 4
Chihuahua 3
Schnauzer - Miniature 2
Terrier - Rat 2
Pit Bull 2
Great Pyrenees 2
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 2

Most Reported Reactions

Vomiting 13
Lack of efficacy (endoparasite) - heartworm 13
Lethargy (see also Central nervous system depression in 'Neurological') 9
Emesis (multiple) 8
Diarrhoea 7
Weight loss 5
Elevated blood urea nitrogen (BUN) 5
Emesis 4
Elevated alanine aminotransferase (ALT) 4
Inappetence 4
Not eating 4
Ataxia 3

Outcome Breakdown

Recovered/Normal
27 (39.1%)
Ongoing
20 (29.0%)
Outcome Unknown
16 (23.2%)
Died
3 (4.3%)
Euthanized
2 (2.9%)
Recovered with Sequela
1 (1.4%)

Data Summary

Metric Value
Total adverse event reports 69
Reports involving death 5
Case-fatality rate (reported events) 720.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Heartworm Preventative Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 69 adverse event reports referencing Heartworm Preventative, including 5 reports in which the animal died — a 720.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Heartworm Preventative. Reported administration routes include Oral, Unknown, Subcutaneous, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Heartworm Preventative reports are Dog (69 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (11), Crossbred Canine/dog (10), Shepherd Dog - German (4) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Heartworm Preventative are Vomiting (13), Lack of efficacy (endoparasite) - heartworm (13), Lethargy (see also Central nervous system depression in 'Neurological') (9), Emesis (multiple) (8). Of the 69 reports with a coded outcome, Recovered/Normal is the leading category at 39.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Heartworm Preventative.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial